Share
270 Posts.
lightbulb Created with Sketch. 39
clock Created with Sketch.
25/09/20
09:07
Share
Originally posted by mrdaxbrown:
↑
Hi James, Just a quick question regarding Cantrixil. I read that Final Data from P1 study was due at ESMO 19-21 September 2020 (Hidden Gems Webinar). Also I noticed that Cantrixil was left out of P16 on the HC Wainwright presentation. Any possible update on this would be appreciated. Thank you for all the work you & the team have been doing & I like many others look forward to the data read outs over the next 6-12 months regarding both Paxalisib & Cantrixil. Regards, MrDB Dear MrDB, After discussion with the investigators, we decided not to put Cantrixil into the ESMO conference. Like many conferences, this has moved to a wholly virtual format, and we took the view that it would not provide good exposure for the final data from the study. We are working to find a better forum to present the definitive results. Meanwhile, as reflected in our more recent guidance, we expect to share at least top-level data in the second half. All best wishes, James. ”we expect to share at least top-level data in the second half” the company has always indicated that they would do a deal / partnership regarding Cantrixil
Expand
Correct me if I'm wrong, but if Kazia is in possession of material information regarding Cantrixil, aren't they required to immediately disseminate to shareholders?